|
|
| Li,Shan; Wang,Xiaoman; Zhang,Jielei; Li,Jingyi; Liu,Xiaogang; Ma,Yuanyuan; Han,Chao; Zhang,Lixia; Zheng,Lili. |
| Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and can lead to life-threatening complications like hepatic carcinoma and cirrhosis. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist antidiabetic drug, has the capacity to overcome insulin resistance and attenuate hepatic steatosis but the specific underlying mechanism is unclear. This study was designed to investigate the underlying molecular mechanisms of exenatide therapy on NAFLD. We used in vivo and in vitro techniques to investigate the protective effects of exenatide on fatty liver via fat mass and obesity associated gene (FTO) in a high-fat (HF) diet-induced NAFLD animal model and related cell culture model. Exenatide significantly... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: GLP-1; FTO; NAFLD; PI3K; Hepatic steatosis. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000800612 |
| |
